Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01780519 · ClinicalTrials.gov registry record · Phase 1
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
A Phase 1 study of Alzheimer's Disease (AD), sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01780519 is a Phase 1 study of Alzheimer's Disease (AD) that has completed, run by Mayo Clinic. The registered enrollment target is 57 participants, below the 376-participant average among 4 other Alzheimer's Disease (AD) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01780519, a Phase 1 study of Alzheimer's Disease (AD), has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.
Conditions Studied
Interventions
- DRUG lorazepam
Study Locations (1)
Arizona
- Mayo Clinic - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01780519
The ClinicalTrials.gov registry entry for NCT01780519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 4 other Alzheimer's Disease (AD) trials with a reported enrollment target (85% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer's Disease (AD) appearing as the primary indexed condition, and to 1 intervention - of which lorazepam is the first listed.
NCT01780519 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01780519 about?
NCT01780519 is a clinical study titled "The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms". The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.
What is the current status of trial NCT01780519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2013-01. Estimated completion is 2016-09.
What conditions does trial NCT01780519 study?
This clinical trial studies the following conditions: Alzheimer's Disease (AD).
What interventions are being tested in trial NCT01780519?
The interventions under investigation include: lorazepam (DRUG).
Who is sponsoring clinical trial NCT01780519?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01780519 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer's Disease (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
RECRUITING · Phase 1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Alzheimer's Disease Neuroimaging Initiative 2
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.